Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-NK Cells for Relapsed/Refractory B-Lymphoid Malignancies
NCT03056339Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19 CAR NK cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), B cell lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2017; status: completed.
02
Drugs
CD19 CAR NK cells
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)B cell lymphoma
Beyond the preview
Go deeper on NCT03056339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056339.